Sodium-Glucose Cotransporter 2 Inhibitor [EPC]

109123 reported adverse events

Drugs of this class: DAPAGLIFLOZIN EMPAGLIFLOZIN DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE BEXAGLIFLOZIN DAPAGLIFLOZIN AND SAXAGLIPTIN EMPAGLIFLOZIN AND LINAGLIPTIN EMPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EMPAGLIFLOZIN, LINAGLIPTIN, METFORMIN HYDROCHLORIDE EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE SOTAGLIFLOZIN

These side effects are most commonly reported by patients taking drugs of the Sodium-Glucose Cotransporter 2 Inhibitor [EPC] class:

# Side effect Count
0 DEATH 6506
1 NAUSEA 5426
2 DIABETIC KETOACIDOSIS 5298
3 DIARRHOEA 5019
4 FATIGUE 4462
5 BLOOD GLUCOSE INCREASED 4409
6 OFF LABEL USE 4406
7 DIZZINESS 4291
8 VOMITING 4280
9 DYSPNOEA 4064
See all common reactions for Sodium-Glucose Cotransporter 2 Inhibitor [EPC]

Drugs of the Sodium-Glucose Cotransporter 2 Inhibitor [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CARDIOSPASM 404 0.7240
1 EUGLYCAEMIC DIABETIC KETOACIDOSIS 2909 0.7038
2 IMMUNISATION 257 0.5922
3 PALMOPLANTAR KERATODERMA 394 0.5434
4 MALIGNANT MEDIASTINAL NEOPLASM 58 0.5273
5 BALANITIS CANDIDA 50 0.3906
6 URINE KETONE BODY 55 0.3374
7 KETOSIS 348 0.3207
8 BLOOD KETONE BODY INCREASED 240 0.3073
9 URINARY TRACT CANDIDIASIS 58 0.3037
See all enriched reactions for Sodium-Glucose Cotransporter 2 Inhibitor [EPC]